Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Clin Infect Dis
; 69(7): 1229-1231, 2019 09 13.
Article
em En
| MEDLINE
| ID: mdl-30933266
ABSTRACT
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Oxazóis
/
Farmacorresistência Bacteriana
/
Tuberculose Extensivamente Resistente a Medicamentos
/
Diarilquinolinas
/
Mycobacterium tuberculosis
/
Nitroimidazóis
/
Antituberculosos
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Infect Dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2019
Tipo de documento:
Article